Opioids Are Not the Only Pain Meds That Can Be Abused

By Dr. Lynn Webster, PNN Columnist

Contrary to popular opinion, opioids don't cause substance abuse. Opioids certainly may be abused, but it is human biology itself that drives drug abuse.

We often get the message that any other pain treatment would be better than using opioids. However, even non-opioids prescribed for pain can contribute to overdoses and suicides. The same genetic and environmental factors that cause opioid abuse can induce abuse of other drugs, too.

For several years the number of opioid prescriptions has declined significantly, due to public demand and political pressure. According to the IQVIA Institute, there was a 17 percent decrease in the number of opioids prescribed in 2018 alone.

We may have expected that to translate into fewer drug abuse problems. Instead, we have seen an increase in overdoses, hospitalizations and suicides involving non-opioids such as gabapentin, methamphetamines and muscle relaxants.

Less access to prescription opioids has driven some people in disabling pain to seek illegal alternative medications. That has led to a wave of use and abuse of drugs that doctors have not prescribed.

Between 2016 and 2017, the CDC reported a nearly 47% increase in fentanyl-related deaths. Overdoses related to methamphetamine and cocaine have also surged.  

According to Stateline, approximately 14,000 cocaine users and 10,000 meth users died in the United States in 2017, triple the number of deaths in 2012. Deaths involving have heroin also spiked since 2010.  

Gabapentin and Baclofen 

Prescription drugs, too, have fueled the negative statistics. Doctors have felt forced to taper or discontinue opioids. In an attempt to find alternatives for pain management, they have increased the number of gabapentin and baclofen prescriptions. 

As PNN has reported, a recent study published in Clinical Toxicology found a “worrying” increase in calls to U.S. poison control centers about gabapentin (Neurontin) and the muscle relaxer baclofen, coinciding with a decrease in opioid prescriptions. The study analyzed more than 90,000 cases of exposure to gabapentin and baclofen, many of which were coded as suicides or attempted suicides.

“Gabapentin and baclofen are two medications that have seen increased availability to patients as alternatives to opioids for the treatment of acute and chronic pain. With greater accessibility, poison center exposures have demonstrated a marked increase in toxic exposures to these two medications,” wrote lead author Kimberly Reynolds of the University of Pittsburgh.

“As poison center data do not represent the totality of cases in the United States, the steep upward trends in reported exposures reflect a much larger problem than the raw numbers would suggest.”  

Gabapentin is one of the most commonly prescribed drugs in the United States. It is prescribed for epilepsy, hot flashes, migraines, nerve damage, and more. It is also used to treat the symptoms of drug and alcohol detoxification, and to treat pain for patients at higher risk of addiction to opioids.  

Baclofen is a muscle relaxant that has also been substituted for opioids. Other non-opioid drugs such as pregabalin and NSAID’s are being increasingly prescribed as well.  

All Medications Have Risks 

Non-opioids have a role to play in pain management, but it is just as important to understand their dangers. While we need effective alternatives to opioids, it is important to know that alternatives also have risks. That is unavoidable, because all medications carry potential benefits and consequences.  

To decide whether a medication is appropriate for an individual, it is critical to determine whether the potential benefit outweighs potential harm. Gabapentin and baclofen are not bad drugs, but they are not harmless replacements for opioids, either.  

No pain medication, whether it is an opioid or non-opioid, is right for everyone under all circumstances. The next time a physician or nurse practitioner suggests replacing an opioid with gabapentin, baclofen, or another medication, it would be appropriate to ask for a comparison of the risks and benefits. 

Talking with your healthcare provider about your preference for a particular medication does not make you a drug seeker. It helps you become an informed patient. 

Lynn R. Webster, MD, is a vice president of scientific affairs for PRA Health Sciences and consults with the pharmaceutical industry. He is the author of the award-winning book, “The Painful Truth,” and co-producer of the documentary, “It Hurts Until You Die.” You can find Lynn on Twitter: @LynnRWebsterMD.

Opinions expressed here are those of the author alone and do not reflect the views or policy of PRA Health Sciences. 

Gabapentin Linked to Growing Number of Suicide Attempts

By Pat Anson, PNN Editor

We’ve reported several times about the abuse and lack of effectiveness of gabapentin, a nerve medication increasingly prescribed to treat fibromyalgia, neuropathy and other types of chronic pain.

It turns out gabapentin is also involved in a growing number of attempted suicides.

In a large new study published in the journal Clinical Toxicology, University of Pittsburgh researchers looked at over 90,000 calls involving medications to U.S. poison control centers. They found that calls about gabapentin and the muscle relaxant baclofen increased significantly just as opioid prescriptions began declining.

“Gabapentin and baclofen are two medications that have seen increased availability to patients as alternatives to opioids for the treatment of acute and chronic pain. With greater accessibility, poison center exposures have demonstrated a marked increase in toxic exposures to these two medications,” wrote lead author Kimberly Reynolds of the University of Pittsburgh.

“As poison center data do not represent the totality of cases in the United States, the steep upward trends in reported exposures reflect a much larger problem than the raw numbers would suggest.”     

Between 2013 and 2017, calls involving the abuse and misuse of gabapentin went up nearly 120 percent, while reports of baclofen being abused or misused rose nearly 32 percent from 2014 to 2017.

Even more concerning is that calls about attempted suicides involving gabapentin rose 80 percent, while calls about attempted suicides with baclofen increased 43 percent. Co-ingestion of sedatives and opioids were common for both medications.

Only 19 deaths involving gabapentin were identified as possible suicides during the five-year study period, but there were thousands of gabapentin-related calls each year coded as attempted suicides — including over 10,000 calls in 2017 alone.

SOURCE: CLINICAL tOXICOLOGY

“It would be anticipated that patients who are prescribed gabapentin and/or baclofen would be more likely to be treated for mood disorders and pain as they are frequently comorbid and therapy overlaps significantly,” researchers said.

“Gabapentin has specifically been recognized for its misuse and diversion potential, synergistic effect with opioid use, and contribution to use disorders. Baclofen misuse has not been as frequently described but is anecdotally observed and associated with severe toxicity, physical dependence, and complicated withdrawal.”

Gabapentin was the 10th-most widely prescribed drug in the U.S. in 2017. Calls to poison control centers about gabapentin were highest in Kentucky and West Virginia, two of the states hardest hit by the opioid crisis. Calls about baclofen were highest in Kentucky, Maine and New Mexico.

The researchers recommend that patients who are prescribed gabapentin or baclofen be prescreened for substance use disorders, mood disorders and suicidal ideation.

FDA Gabapentin Warning

The Food and Drug Administration warned in 2008 that all patients being treated with gabapentin or ten other antiepileptic drugs should be informed about the risks of suicidal thoughts and actions.

The FDA reviewed 199 clinical trials of the drugs and found that patients who received them had almost twice the risk of suicidal behavior or ideation (0.43%) than patients on a placebo (0.24%). That means there would be one additional case of suicidal thinking or behavior for every 530 patients treated with an antiepileptic drug.

“All patients who are currently taking or starting on any antiepileptic drug for any indication should be monitored for notable changes in behavior that could indicate the emergence or worsening of suicidal thoughts or behavior or depression,” the FDA said.

Gabapentin (Neurontin) and its chemical cousin pregabalin (Lyrica) belong to a class of nerve medication called gabapentinoids. Both drugs were originally developed to treat epileptic seizures, but are now widely prescribed off label to treat a variety of chronic pain conditions.    

A recent Swedish study found that patients taking gabapentinoids had higher rates of overdose, suicide and suicidal behavior than the general population. The risks were strongest in teens and young adults.

A recent clinical review found little evidence that gapapentinoids should be used off-label to treat pain and that prescribing guidelines often exaggerate their effectiveness. The CDC’s controversial 2016 opioid guideline, for example, calls gabapentin and pregabalin “first-line drugs” for neuropathic pain.

In a new draft report being funded by the CDC, researchers say gabapentin showed only “small improvements” in pain for people with diabetic peripheral neuropathy and fibromyalgia. The study by the Agency for Healthcare Research and Quality (AHRQ) is expected to finalized in early 2020.